419 related articles for article (PubMed ID: 28892528)
1. Determinants of Market Exclusivity for Prescription Drugs in the United States.
Kesselheim AS; Sinha MS; Avorn J
JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
[TBL] [Abstract][Full Text] [Related]
2. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
3. Strategies That Delay Market Entry of Generic Drugs.
Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A
JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217
[TBL] [Abstract][Full Text] [Related]
4. Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018.
Rome BN; Lee CC; Kesselheim AS
Clin Pharmacol Ther; 2021 Feb; 109(2):367-371. PubMed ID: 32654122
[TBL] [Abstract][Full Text] [Related]
5. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
[TBL] [Abstract][Full Text] [Related]
6. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
Levy MS
Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
[TBL] [Abstract][Full Text] [Related]
7. Updated trends in US brand-name and generic drug competition.
Grabowski H; Long G; Mortimer R; Boyo A
J Med Econ; 2016 Sep; 19(9):836-44. PubMed ID: 27064194
[TBL] [Abstract][Full Text] [Related]
8. Generic Drugs in the United States: Policies to Address Pricing and Competition.
Gupta R; Shah ND; Ross JS
Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089
[TBL] [Abstract][Full Text] [Related]
9. Recent trends in brand-name and generic drug competition.
Grabowski H; Long G; Mortimer R
J Med Econ; 2014 Mar; 17(3):207-14. PubMed ID: 24320785
[TBL] [Abstract][Full Text] [Related]
10. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
Wineinger NE; Zhang Y; Topol EJ
JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
[TBL] [Abstract][Full Text] [Related]
11. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
12. A Method for Approximating Future Entry of Generic Drugs.
Beall RF; Darrow JJ; Kesselheim AS
Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
[TBL] [Abstract][Full Text] [Related]
13. Variations in time of market exclusivity among top-selling prescription drugs in the United States.
Wang B; Liu J; Kesselheim AS
JAMA Intern Med; 2015 Apr; 175(4):635-7. PubMed ID: 25664700
[No Abstract] [Full Text] [Related]
14. Strategic options for brand-name prescription drugs when patents expire.
Mehta SC; Mehta SS
Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
[TBL] [Abstract][Full Text] [Related]
15. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
Hong SH; Shepherd MD; Scoones D; Wan TT
J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
[TBL] [Abstract][Full Text] [Related]
16. How will recent trade agreements that extend market protections for brand-name prescription pharmaceuticals impact expenditures and generic access in Canada?
Beall RF; Hardcastle L; Clement F; Hollis A
Health Policy; 2019 Dec; 123(12):1251-1258. PubMed ID: 31601457
[TBL] [Abstract][Full Text] [Related]
17. New Drug Formulations and Their Respective Generic Entry Dates.
Beall RF; Kesselheim AS; Sarpatwari A
J Manag Care Spec Pharm; 2019 Feb; 25(2):218-224. PubMed ID: 30698097
[TBL] [Abstract][Full Text] [Related]
18. Competition in prescription drug markets: the roles of trademarks, advertising, and generic names.
Feldman R; Lobo F
Eur J Health Econ; 2013 Aug; 14(4):667-75. PubMed ID: 22815099
[TBL] [Abstract][Full Text] [Related]
19. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
[TBL] [Abstract][Full Text] [Related]
20. Market exclusivity for top-selling pharmaceuticals: too long, too short, or just right?
Downing NS
JAMA Intern Med; 2015 Apr; 175(4):637-8. PubMed ID: 25664529
[No Abstract] [Full Text] [Related]
[Next] [New Search]